Merck Said to Be in Talks to Buy Cubist for $7 Billion

Updated on

Merck & Co. is in talks to acquire Cubist Pharmaceuticals Inc., a maker of antibiotics, in a deal valued at more than $7 billion, a person familiar with the matter said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.